Combining PARP inhibitors With Other Treatments for Men With Prostate Cancer: Clinical Trial Updates
In this podcast episode, listen to medical oncologists Karim Fizazi, MD, PhD, and Joaquin Mateo, MD, PhD, discuss the latest results from ongoing and planned clinical trials using PARP inhibitors in combination with other therapies to treat men with prostatic cancer.
Decera Clinical Education Oncology Podcast · Karim Fizazi MD PhD, Joaquin Mateo MD PhD
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode, Karim Fizazi, MD, PhD, and Joaquin Mateo, MD, PhD, consider the potential implications of ongoing and planned clinical trials using PARP inhibitors in combination with other therapies to treat men with prostate cancer including:
- PARP inhibitors combined with androgen receptors
- Phase III trials of PARP inhibitors with androgen receptor–directed therapy
- PARP inhibitors combined with immunotherapy
- PARP inhibitors and DNA damaging agents
Presenters:
Karim Fizazi, MD, PhD
Full Professor
Cancer Medicine
Institut Gustave Roussey
Villejuif, France
Joaquin Mateo, MD, PhD
Attending Physician
Medical Oncology
Vall d’Hebron University Hospital,
Barcelona, Spain
Content is part of an online program supported by an educational grant from Pfizer Inc.
Link to full program, including associated downloadable Podcast Pearls slidesets, expert analysis, and expert commentary:
https://bit.ly/3spLzqa
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.